Thymosin Alpha-1 is a thymic peptide that enhances adaptive immunity via T-cell maturation and cytokine modulation; LL-37 is the only human cathelicidin, acting as a direct antimicrobial and innate immune modulator — two complementary arms of the immune response.
Research reference only — all information on this page summarises peer-reviewed scientific literature and does not constitute medical advice. View full compound profiles: Thymosin Alpha-1 · LL-37
Mechanism Comparison
Thymosin Alpha-1 (Tα1) is a 28-amino-acid peptide originally isolated from thymosin fraction 5. It acts primarily through Toll-like receptor 9 (TLR9) signalling, activating dendritic cells and promoting Th1 polarisation. It enhances NK cell activity, upregulates MHC class II expression, and promotes T-regulatory cell function — its immunomodulatory profile is broadly described as "normalising" rather than simply stimulatory. LL-37 is the C-terminal domain of the cathelicidin precursor protein hCAP18 (18 kDa), generated by proteinase 3 cleavage. It disrupts bacterial membranes via amphipathic helix insertion, neutralises LPS/LTA endotoxins, and activates innate immune pathways through FPRL1, TLR2/TLR4/TLR9, and purinergic receptor signalling. Additionally, LL-37 is chemotactic for neutrophils, monocytes, and mast cells.
Side-by-Side Attributes
| Attribute | Thymosin Alpha-1 | LL-37 |
|---|---|---|
| Peptide origin | Thymus — isolated from thymosin fraction 5 | Cathelicidin family — processed from hCAP18 (neutrophils, epithelium) |
| Amino acid count | 28 amino acids | 37 amino acids |
| Molecular weight | 3108.4 g/mol | 4493.3 g/mol |
| CAS number | 62304-98-7 | 154947-66-7 |
| Primary immune target | Adaptive immunity — T-cell maturation, Th1 polarisation | Innate immunity — antimicrobial, LPS neutralisation, chemotaxis |
| Primary mechanism | TLR9 signalling; dendritic cell activation; NK enhancement | Membrane disruption; FPRL1 / TLR2/4/9 activation; chemotaxis |
| Direct antimicrobial activity | Indirect (via immune activation) | Direct — membrane-disrupting MIC documented for bacteria, fungi, viruses |
| Regulatory status | Approved in 35+ countries; investigational in US | Investigational; endogenous human peptide |
| Clinical trial data | Phase 3 (TESTS trial, sepsis): primary endpoint not met (BMJ 2025) | Phase 1/2 data in wound healing; mostly preclinical |
Key Research Points
- 1Thymosin Alpha-1 is approved as Zadaxin® in over 35 countries for hepatitis B, hepatitis C, and immune adjuvancy in cancer — giving it the most substantial clinical evidence base of any immunomodulatory research peptide in this niche.
- 2LL-37 is the only cathelicidin expressed in humans — making it the primary antimicrobial peptide of innate immune defence, with direct killing activity against gram-positive and gram-negative bacteria, fungi, and enveloped viruses. This direct antimicrobial property is absent in Thymosin Alpha-1.
- 3The TESTS trial (BMJ, January 2025), the largest randomised trial of Thymosin Alpha-1 to date (n=1,106 sepsis patients), did not meet its primary mortality endpoint — a significant update to the clinical evidence base that researchers must account for when reviewing Thymosin Alpha-1 efficacy claims.
- 4LL-37 has dual wound-healing research utility: beyond antimicrobial activity, it promotes angiogenesis (via VEGFR2 transactivation), fibroblast migration, and re-epithelialisation — making it studied in wound healing as well as infection models.
- 5These compounds target complementary arms of the immune response and are sometimes studied together in models of immunocompromise — Thymosin Alpha-1 for adaptive immune restoration, LL-37 for innate antimicrobial defence. This is particularly relevant in post-chemotherapy immunosuppression models.
Frequently Asked Questions
What is the difference between Thymosin Alpha-1 and LL-37?
Thymosin Alpha-1 is a 28-amino-acid thymic peptide that modulates adaptive immunity: it activates dendritic cells via TLR9, promotes Th1 cytokine polarisation, enhances NK cell activity, and upregulates MHC class II expression — broadly normalising immune function. LL-37 is the only human cathelicidin (37 amino acids), acting primarily in innate immunity: it directly disrupts bacterial membranes, neutralises LPS endotoxins, and activates innate immune pathways through FPRL1 and TLR signalling. In sum: Thymosin Alpha-1 is an adaptive immune modulator; LL-37 is a direct antimicrobial and innate immune activator.
Is Thymosin Alpha-1 FDA-approved?
Thymosin Alpha-1 (Zadaxin®) is approved in over 35 countries for hepatitis B, hepatitis C, and as an immune adjuvant in certain cancer protocols, primarily in Asia, Eastern Europe, and Latin America. It is not FDA-approved in the United States, where it remains investigational. The January 2025 publication of the TESTS trial (BMJ), the largest randomised controlled trial of Thymosin Alpha-1 in sepsis (n=1,106), did not demonstrate a statistically significant reduction in 28-day mortality — a key update to the clinical evidence base.
Does LL-37 have direct antibacterial activity?
Yes — LL-37 is a directly antimicrobial peptide with published minimum inhibitory concentration (MIC) data against a broad spectrum of gram-positive bacteria (S. aureus, S. epidermidis), gram-negative bacteria (E. coli, P. aeruginosa), fungi, and enveloped viruses. Its mechanism involves intercalation into microbial membranes via an amphipathic alpha-helix, disrupting membrane integrity and leading to cell lysis. This direct antimicrobial mechanism is distinct from Thymosin Alpha-1, which has no direct killing activity and acts entirely through immune cell signalling.
Deep Dive
For extended mechanism analysis, trial data, and regulatory context, see the full research article:
Thymosin Alpha-1 vs LL-37: Immunomodulatory Peptide Research Comparison →Full compound profile
Thymosin Alpha-1
Full compound profile
LL-37